NCT03054909 - IP ALT-803 Followed by SQ ALT-803 for Ovarian Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 19, 2017

Primary Completion Date

February 16, 2022

Study Completion Date

February 16, 2022

Conditions

FIGO Stage III and IV Ovarian CancerFIGO Stage III and IV Fallopian Tube CancerFIGO Stage III Primary Peritoneal Cancer

Interventions

BIOLOGICAL

ALT-803 Subcutaneous

Patient receives ALT-803 10 mcg/kg subcutaneous weekly x 4 followed by 4 weeks of no treatment before continuing with treatment courses 2, 3, and 4. Treatment courses 2, 3, and 4 are identical for all patients - ALT-803 10 mcg/kg subcutaneous weekly x 4 with a 4 week rest (4 weeks on/4 weeks off)

BIOLOGICAL

ALT-803 Intraperitoneal

Patient receives ALT-803 10 mcg/kg intraperitoneal weekly x 4 weeks followed by 4 weeks of no treatment before continuing with treatment courses 2, 3, and 4. Treatment courses 2, 3, and 4 are identical for all patients - ALT-803 10 mcg/kg subcutaneous weekly x 4 with a 4 week rest (4 weeks on/4 weeks off).

Trial Locations (1)

55455

Masonic Cancer Center, University of Minnesota, Minneapolis

All Listed Sponsors

lead

Masonic Cancer Center, University of Minnesota

OTHER